DNA Personalized Product Integration & Development

Easily Harness the Power of DNA-Based Product Personalization for your Health & Wellness Product Development Strategy using Saliva.

Data Sheet
Start Integrating DNA Personalization into your Direct-to-Consumer Products
DNA Personalized Product Development
SDNA Saliva Collection Device Molecular Diagnostic

Saliva Adds Highly-Valuable
Diagnostic Benefits

In spite of advances in diagnostics and therapeutics, cancer remains the second leading cause of death in the U.S. Successful cancer treatments depend not only on better therapies but the critical ability to detect cancer at its earliest stage when treatment is radically more successful.

Cancer is a highly individualized disease. Liquid biopsy using saliva can deliver early detection with the crucial disease data needed for informed, personalized treatments. Spectrum’s saliva collection system is engineered and formulated to maintain quality and critical bio-sample consistency. Two highly pivotal elements essential to understanding cancer and successfully optimizing treatments.

Traditional tumor biopsies remain costly and invasive. Often, when analysis is possible, the tumor is already settled or even in a metastatic state. Additionally, tissue biopsy only provides a single snapshot of the molecular aberration in the tumor at that specific time. New saliva-based liquid biopsies using cell-free circulating tumor DNA (ctDNA) offer a holistic insight into the whole tumor landscape.

Easy, convenient, noninvasive, and pain-free at-home sample self-collection offers patients repeat saliva sampling over extended periods of time. This activity enables the continuous monitoring of treatment response or the emergence of drug resistance. Additionally, the benefit of detecting additional disease activity and mutations help prevent relapses during the course of the disease and beyond for lifelong cancer-free confirmation. While saliva tests won’t replace blood tests for all diagnostic applications, this innovative cancer testing solution has proven to be an incredibly valuable life-saving alternative.

*Testing Availability End of 2021

SDNA Saliva Collection Device Molecular Diagnostic

Saliva Adds Highly-Valuable Diagnostic Benefits

In spite of advances in diagnostics and therapeutics, cancer remains the second leading cause of death in the U.S. Successful cancer treatments depend not only on better therapies but the critical ability to detect cancer at its earliest stage when treatment is radically more successful.

Cancer is a highly individualized disease. Liquid biopsy using saliva can deliver early detection with the crucial disease data needed for informed, personalized treatments. Spectrum’s saliva collection system is engineered and formulated to maintain quality and critical bio-sample consistency. Two highly pivotal elements essential to understanding cancer and successfully optimizing treatments.

Traditional tumor biopsies remain costly and invasive. Often, when analysis is possible, the tumor is already settled or even in a metastatic state. Additionally, tissue biopsy only provides a single snapshot of the molecular aberration in the tumor at that specific time. New saliva-based liquid biopsies using cell-free circulating tumor DNA (ctDNA) offer a holistic insight into the whole tumor landscape.

Easy, convenient, noninvasive, and pain-free at-home sample self-collection offers patients repeat saliva sampling over extended periods of time. This activity enables the continuous monitoring of treatment response or the emergence of drug resistance. Additionally, the benefit of detecting additional disease activity and mutations help prevent relapses during the course of the disease and beyond for lifelong cancer-free confirmation. While saliva tests won’t replace blood tests for all diagnostic applications, this innovative cancer testing solution has proven to be an incredibly valuable life-saving alternative.

*Testing Availability End of 2021

Chemistry Enables Earliest Cancer Detection

34% of Cancer Biomarkers Identified in Saliva

Test Identifies Cell-Free DNA shed by Tumers

Saliva is an excellent source of high-quality genomic DNA (gDNA)

74% of DNA in saliva comes from white blood cells

Download Data Sheet

A Better
Diagnostic Tool

  • DNA found in saliva is equivalent in quantity & purity to DNA in blood

  • Saliva provides inexpensive and at-home testing reducing affordability & accessibility barriers to early diagnosis

  • Spectrum’s Saliva Liquid Biopsy uses PCR testing and a proprietary assay to accurately identify cell-free circulating tumor DNA (ctDNA)

  • Collection system removes the need for any temperature-controlled storage or transport of testing samples

  • First saliva-based PCR protein preservation solution for qualitative and quantitative early cancer detection (patent-pending)

  • DNA solution’s proprietary formulation delivers higher yields of both single-stranded short and double-stranded ultrashort DNA compared to samples using only raw saliva

  • Saliva collection system & preservation chemistry delivers critical sample consistency for optimal testing accuracy

Easy, Early, and
Pain-Free Detection

UCLA Research shows saliva tests using Spectrum’s saliva collection device and preservation chemistry provide cancer detection at its earliest stages well before even imaging scans are able to locate it. Cancer treatment has shown to be the most successful when cancer is detected early giving patients not only time but more clinical and therapeutic options.

In addition, regular, repeat at-home saliva testing allows clinical teams to monitor and optimize treatment plans over time as the disease progression changes or to confirm cancer remission year over year.

*Testing Availability End of 2021

Screening, Detection, & Monitoring

For over 150 years proteins have provided vital early indicators of disease. Recent research has identified and cataloged 2290 proteins in whole saliva so far (plasma holds 2698 proteins). Out of all known proteins, 1058 proteins have been identified as cancer biomarkers and 34% have already been found in saliva. To date, 40% of proteins found have been identified as biomarkers for diseases including cancer, cardiovascular disease, and stroke.

*Testing Availability End of 2021

Screening, Detection, & Monitoring

For over 150 years proteins have provided vital early indicators of disease. Recent research has identified and cataloged 2290 proteins in whole saliva so far (plasma holds 2698 proteins). Out of all known proteins, 1058 proteins have been identified as cancer biomarkers and 34% have already been found in saliva. To date, 40% of proteins found have been identified as biomarkers for diseases including cancer, cardiovascular disease, and stroke.

*Testing Availability End of 2021

Saliva Diagnostic UCLA
Research Collaboration Success

Early Cancer Detection  |  Monitoring Treatment Response  |  Analysis of Resistance  |  Detection of Recurrence

Contact Us

Can we answer any questions?

Let's Connect

#partofthesolution

Associations, Memberships & Credentials